Startups
Acquisitions / Manufacturing

Emergent Biosolutions will move manufacturing of anthrax treatment to Baltimore

The life sciences company acquired the drug from GlaxoSmithKline.

Tender Hearts helps families in their times of need. (Photo via Tender Hearts/Facebook)

Emergent Biosolutions doubled the size of its manufacturing facility in Bayview earlier this year. With an acquisition deal announced Wednesday, the life sciences company now has plans for the primary product that will be made there.
The Gaithersburg-based multinational is set to purchase an anthrax treatment from pharmaceutical giant GlaxoSmithKline in a deal that could be worth up to $96 million.
EBS is purchasing raxibacumab, an FDA-approved drug that treats inhaled anthrax. It already has the attention of the U.S. government. The deal also includes a federal contract to manufacture the antidote for the U.S. National Stockpile, which the country keeps in case of emergency.
 
“We’ve concluded that this is the product of choice for the U.S. government,” Emergent Biosolutions CEO Daniel J. Abdun-Nabi said on a Wednesday afternoon conference call with investors. It’s an interesting move for a company that got lots of attention for developing an FDA-approved anthrax vaccine. Abdun-Nadi said he believes the two products are “complementary.”
The company plans to move manufacturing of the its newly-acquired vaccine to Baltimore in 2020. It will be the anchor product at the Bayview facility, where bulk manufacturing will take place. The 112,000 sq. ft. spot is one of three Centers for Innovation in Advanced Development and Manufacturing that the U.S. Health and Human Services Department has designated to call if quick vaccine production is needed.
EBS’ other Baltimore manufacturing facility in Carroll-Camden will handle the fill/finish process.

Before you go...

Please consider supporting Technical.ly to keep our independent journalism strong. Unlike most business-focused media outlets, we don’t have a paywall. Instead, we count on your personal and organizational support.

3 ways to support our work:
  • Contribute to the Journalism Fund. Charitable giving ensures our information remains free and accessible for residents to discover workforce programs and entrepreneurship pathways. This includes philanthropic grants and individual tax-deductible donations from readers like you.
  • Use our Preferred Partners. Our directory of vetted providers offers high-quality recommendations for services our readers need, and each referral supports our journalism.
  • Use our services. If you need entrepreneurs and tech leaders to buy your services, are seeking technologists to hire or want more professionals to know about your ecosystem, Technical.ly has the biggest and most engaged audience in the mid-Atlantic. We help companies tell their stories and answer big questions to meet and serve our community.
The journalism fund Preferred partners Our services
Engagement

Join our growing Slack community

Join 5,000 tech professionals and entrepreneurs in our community Slack today!

Trending

The Trump rally shooter perched on a building owned by American Glass Research. Here’s everything we know about it.

Quantum computing could be the next hot tech — if only that breakthrough would come

From global juggernauts to local government, this developer never stops serving

Despite EDA decision, the Baltimore Tech Hub is still possible: Kory Bailey

Technically Media